Form 4: Celcuity CFO Granted 80,000 Stock Options

Celcuity Inc.'s Chief Financial Officer, Vicky Hahne, was granted 80,000 stock options with a vesting schedule extending to 2026 and beyond.

Summary

• Vicky Hahne, Chief Financial Officer of Celcuity Inc. (CELC), was granted 80,000 stock options.
• The transaction date for this grant was August 18, 2025.
• The exercise price for these stock options is $51.57 per share.
• The options have an expiration date of August 18, 2035.
• The vesting schedule for the options is as follows: 20,000 shares vest on August 18, 2026, and the remaining 60,000 shares vest at a rate of 1/36th per month thereafter.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the grant itself is a standard compensation event, it reflects a commitment to long-term executive retention and incentive alignment, which is generally viewed favorably by investors.

Positives

• The grant of stock options aligns the Chief Financial Officer's long-term incentives with shareholder value creation, as the options gain value only if the company's stock price increases above the exercise price.
• This compensation structure is a common method to retain key executives and motivate performance over an extended period.

Negatives

• The exercise of these options in the future could lead to dilution for existing shareholders, as new shares would be issued.

Risks

• The value of the stock options is contingent on the future market price of Celcuity Inc.'s common stock; if the stock price does not exceed the exercise price of $51.57, the options may expire worthless.
• The vesting schedule requires continued employment, and forfeiture of unvested options would occur if the CFO's employment terminates before vesting dates.

Future Outlook

The grant of long-term stock options suggests an expectation of future growth and value creation for Celcuity Inc., as the options are designed to incentivize the Chief Financial Officer to contribute to the company's long-term success.

Industry Context

The granting of stock options to key executives like the Chief Financial Officer is a standard practice in the biotechnology and pharmaceutical industries, where long-term value creation through research, development, and commercialization is paramount. This compensation method is widely used to align executive interests with shareholder returns over multi-year periods.

Comparison to Industry Standards

• The grant of 80,000 stock options to a CFO is within the typical range for executive compensation in growth-oriented biotech companies, though specific comparisons would require detailed peer group analysis of companies with similar market capitalization and development stages.
• The 10-year expiration period (until August 18, 2035) is a common duration for executive stock options, providing a long-term incentive horizon.
• The vesting schedule, with an initial cliff vesting followed by monthly installments, is a standard approach to ensure executive retention and sustained performance over several years.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from incentivized management performance.
• Employees (CFO): Direct impact on the Chief Financial Officer's potential future compensation and long-term financial incentives.

Next Steps

• The stock options will begin to vest on August 18, 2026, with subsequent monthly vesting for the remaining shares.
• The Chief Financial Officer may choose to exercise the vested options at any point before their expiration on August 18, 2035, provided the stock price is above the exercise price.

Key Dates

Recommendation

This Form 4 filing details a routine stock option grant to a key executive as part of their compensation. It does not provide new information regarding the company's financial performance, strategic direction, or operational results that would warrant a change in investment recommendation. While it aligns executive incentives, it's a standard event and not a catalyst for significant price movement. Investors should continue to evaluate Celcuity Inc. based on its core business fundamentals and broader market conditions.

Keywords

Celcuity Inc., CELC, Stock Options, Executive Compensation, Form 4, Insider Transaction, Vicky Hahne, CFO